Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

But last week, those words took on the force of law. On Tuesday, Texas Attorney General Ken Paxton filed a lawsuit against ...

AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...

The outbreak of the COVID-19 pandemic demonstrated the need to rapidly develop, produce and distribute large quantities of ...

Ajinomoto Bio-Pharma Services and Olon S.p.A. have entered into a strategic partnership to deliver drug substance manufacturing services.

Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.

The partnership will accelerate efficient and sustainable manufacturing of high-demand proteins and peptides, such as GLP-1 analogs, for pharmaceutical and biotechnology clients TOKYO ...

The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to ...

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi ArabiaRIYADH, Saudi Arabia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre ...